EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Is the risk of venous thromboembolic disease truly an absolute contraindication for menopause hormone therapy?

Tomáš Fait iD, S Šimková iD, V Dvořáková iD

Česká gynekologie · 22.10.2026 · 91 (5) · 408-416

DOI: 10.48095/cccg2026408 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Česká gynekologie, online erschienen am 23.10.2026. Verfasst von Tomáš Fait und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Venous Thromboembolism, Estrogen Replacement Therapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral menopause hormone therapy (MHT) is associated with a two- to four-fold increased risk of venous thromboembolism (VTE). According to the majority of studies, the increased risk of venous thromboembolic disease does not apply to transdermal administration. Transdermal MHT is considered safe even in women at a high risk of thromboembolic disease (such as those with overweight, obesity, thrombophilic conditions, recent surgery, immobilization, varicose veins, malignancy, or smoking). Acute VTE represents an absolute contraindication to both oral and transdermal administration of MHT. A personal history of VTE is an absolute contraindication to oral MHT, but only a relative contraindication for the transdermal route of MHT. Menopause hormone therapy must be personalized for each woman. Key words: menopause hormone therapy – transdermal application – venous thromboembolic disease – thrombophilic mutation – overweight – chronic estrogen deficiency

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismEstrogen Replacement TherapyHumansFemaleAdministration, CutaneousAdministration, OralRisk FactorsContraindications, DrugContraindications

Stichwörter der Autor:innen

chronic estrogen deficiencymenopause hormone therapyoverweightprescribing recommendationsthrombophilic mutationtransdermal applicationvenous thromboembolic diseasevenous thromboembolism

Autor:innen und Institutionen

ORCID-Profile: Tomáš Fait, S Šimková, V Dvořáková

Zitieren

APA

Fait, T., Šimková, S., & Dvořáková, V. (2026). Is the risk of venous thromboembolic disease truly an absolute contraindication for menopause hormone therapy?. Česká gynekologie, 91(5), 408-416. https://doi.org/10.48095/cccg2026408

Vancouver

Fait T, Šimková S, Dvořáková V. Is the risk of venous thromboembolic disease truly an absolute contraindication for menopause hormone therapy?. Česká gynekologie. 2026;91(5):408-416. doi:10.48095/cccg2026408

BibTeX
@article{Fait2026,
  author = {Fait, Tomáš and Šimková, S and Dvořáková, V},
  title = {Is the risk of venous thromboembolic disease truly an absolute contraindication for menopause hormone therapy?},
  journal = {Česká gynekologie},
  year = {2026},
  volume = {91},
  number = {5},
  pages = {408--416},
  doi = {10.48095/cccg2026408}
}
Kostenlos starten →